Hims & Hers rolls out unapproved peptides with a massive warning
Hims & Hers launched a Peptides+ platform offering five new compounded peptide and longevity treatments, though the company admits its data on efficacy is still thin. While 10,000 users signed up in just 15 days, health experts and the company’s CMO admit the products are being used without full clinical data.
- Original source: cnbc.com.
- The source published it on Nov 18, 2026 at 2:02 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Hims & Hers just dropped a Peptides+ platform, rolling out five new compounded peptide and longevity treatments made right here in the U.S. Even with the big debut, the company is already throwing out a caveat: they still have a lot to learn about exactly how these peptides work.
The new lineup includes formulations of sermorelin, glutathione, NAD+, compounded vitamin B-12, and L-carnitine. These powerful, unapproved peptides have already captured massive interest, with over 10,000 people signing up for the early access list within 15 days, according to a company spokesperson.
While Hims confirms its treatments are not yet approved by the FDA, they say they are legally operating through licensed pharmacies that meet high quality standards. The company plans to expand its offerings to include even more unapproved options like BPC-157 and TB-500.
However, Hims Chief Medical Officer Dr. Anant Vinjamoori warned that they lack the typical data seen with established compounds. He stressed that they may need to adjust dosages or refer patients to other care options based on real-world results.
The push by Hims is facing heat from health experts. Chemistry professor Joshua Kritzer cautioned that without large-scale clinical trials, users are relying on anecdotal information—which he says is nowhere near enough to put a substance into your body.
Cell biology professor Paul Knoepfler flagged dosing as a major concern, noting that the 'goosey' nature of these products makes it impossible to know the safest or most effective amounts to use without formal testing, and warns of potential immune responses that could be very bad for one's health.
TopicsHims & Hers · Andrew Huberman · Anant Vinjamoori · Robert F. Kennedy Jr.
Source: cnbc.com
Written by AI from verified reporting.
More stories
- Health & science medicalxpress.com Caught by @lantern129 0 viewsDNA rewires how your cells answer alcohol, nicotine and caffeine
- Health & science hindustantimes.com 0 viewsICMR wires up 70 labs into an outbreak early-warning grid
- Health & science theguardian.com 1 viewWellcome puts £9.3m into first major study of UK's under-16 social media ban
- Health & science theguardian.com Caught by @Crypto fresh 2 viewsViagra-Style Pill Slows Alzheimer's Decline by 31% in Global Trial

